dc.contributor
Institut Català de la Salut
dc.contributor
[Casacuberta-Serra] Peptomyc S.L., Barcelona, Spain. [Gonzalez-Larreategui I] Models of Cancer Therapies Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Soucek L] Peptomyc S.L., Barcelona, Spain. Models of Cancer Therapies Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Casacuberta-Serra, Sílvia
dc.contributor.author
González-Larreategui, Íñigo
dc.contributor.author
Soucek, Laura
dc.date.accessioned
2025-10-25T05:39:28Z
dc.date.available
2025-10-25T05:39:28Z
dc.date.issued
2024-01-17T10:29:19Z
dc.date.issued
2024-01-17T10:29:19Z
dc.date.issued
2023-12-26
dc.identifier
Casacuberta-Serra S, Gonzalez-Larreategui I, Soucek L. eIF4A dependency: the hidden key to unlock KRAS mutant non-small cell lung cancer’s vulnerability. Transl Lung Cancer Res. 2023 Dec 26;12(12):2570–5.
dc.identifier
https://hdl.handle.net/11351/10875
dc.identifier
10.21037/tlcr-23-682
dc.identifier.uri
http://hdl.handle.net/11351/10875
dc.description.abstract
MYC; Non-small cell lung cancer
dc.description.abstract
MYC; Càncer de pulmó de cèl·lules no petites
dc.description.abstract
MYC; Cáncer de pulmón de células no pequeñas
dc.description.abstract
The authors received funding support by the “Proyectos de I+D+i en Líneas Estratégicas” (PLEC2021-007959) grant from the Spanish Ministry of Economy and Competitiveness; La Marató TV3 grant [2019429]; and the 2nd BBVA Foundation Comprehensive Program of Cancer Immunotherapy & Immunology (CAIMI-II) grant. I.G.L. was supported by a grant from the University Teacher Training Program (FPU), Ministry of Universities (FPU20/04812). Authors from VHIO acknowledge the State Agency for Research (Agencia Estatal de Investigación) the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033).
dc.format
application/pdf
dc.publisher
AME Publishing
dc.relation
Translational Lung Cancer Research;12(12)
dc.relation
https://doi.org/10.21037/tlcr-23-682
dc.relation
info:eu-repo/grantAgreement/ES/PE2017-2020/FPU20%2F04812
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Pulmons - Càncer - Tractament
dc.subject
Anomalies cromosòmiques
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación
dc.title
eIF4A dependency: the hidden key to unlock KRAS mutant non-small cell lung cancer’s vulnerability
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
